Scientist ‘pops the hood’ on US pork industry’s newest vaccine for PCV2

What is “cell-mediated immunity“ and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?
calendar icon 29 November 2018
clock icon 2 minute read

In an interview with Pig Health Today, veterinary immunologist Meggan Bandrick, DVM, PhD, popped the hood on the US pork industry’s newest PCV2 vaccine and answered these questions in practical terms.

Watch the full interview or each part separately:

Full interview: What’s under the hood? Veterinary immunologist explains merits of new PCV2 vaccine

Part 1: Cell-mediated immunity critical to vaccine performance

Part 2: Why two PCV2 genotypes are better than one

Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage

© 2000 - 2022 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.